Genetically modified «hunter» T cells successfully migrated to and penetrated
a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat this aggressive cancer, Penn Medicine researchers report in a new study this week in Science Translational Medicine.
Baliga's group is also mapping networks in patients with glioblastoma, a particularly
deadly type of brain tumor.
That genetic map led to key insights, such as the link between glioblastoma,
the deadliest type of brain tumor, and a gene called BEX1.
Not exact matches
Northwestern Medicine scientists have identified a small RNA molecule called miR - 182 that can suppress cancer - causing genes in mice with glioblastoma mulitforme (GBM), a
deadly and incurable
type of brain tumor.